Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”

SIMPLE SUMMARY: Patients with HER-2 positive breast cancer who progress through available HER2-targeted therapy, at present, have few effective treatment options. PIK3CA is mutated in approximately 20% of HER2 positive breast cancers, contributes to HER-2 therapy resistance and may be predictive of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Keegan, Niamh M., Furney, Simon J., Walshe, Janice M., Gullo, Giuseppe, Kennedy, M. John, Smith, Diarmuid, McCaffrey, John, Kelly, Catherine M., Egan, Keith, Kerr, Jennifer, Given, Mark, O’Donovan, Peter, Hernando, Andres, Teiserskiene, Ausra, Parker, Imelda, Kay, Elaine, Farrelly, Angela, Carr, Aoife, Calzaferri, Giulio, McDermott, Ray, Keane, Maccon M., Grogan, Liam, Breathnach, Oscar, Morris, Patrick G., Toomey, Sinead, Hennessy, Bryan T.
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7999809/
https://ncbi.nlm.nih.gov/pubmed/33799597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados